NDC 73207-101

QINLOCK

Ripretinib

QINLOCK is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Deciphera Pharmaceuticals, Llc. The primary component is Ripretinib.

• Product ID: 73207-101_0bac7a42-cfdd-4b31-8c15-5a055005638c
• NDC: 73207-101
• Product Type: Human Prescription Drug
• Proprietary Name: QINLOCK
• Generic Name: Ripretinib
• Dosage Form: Tablet
• Route of Administration: ORAL
• Marketing Start Date: 2020-05-15
• Marketing Category: NDA / NDA
• Application Number: NDA213973
• Labeler Name: Deciphera Pharmaceuticals, LLC
• Substance Name: RIPRETINIB
• Active Ingredient Strength: 50 mg/1
• Pharm Classes: Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], Platelet-derived Growth Factor alpha Receptor Inhibitors [MoA], Stem Cell Factor (KIT) Receptor Inhibitors [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2024-12-31

Packaging

NDC 73207-101-30

1 BOTTLE in 1 CARTON (73207-101-30) > 90 TABLET in 1 BOTTLE

• Marketing Start Date: 2020-05-15
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 73207-101-30 [73207010130]

QINLOCK TABLET

• Marketing Category: NDA
• Application Number: NDA213973
• Product Type: HUMAN PRESCRIPTION DRUG
• Marketing Start Date: 2020-05-15

NDC 73207-101-31 [73207010131]

QINLOCK TABLET

• Marketing Category: NDA
• Application Number: NDA213973
• Product Type: HUMAN PRESCRIPTION DRUG
• Marketing Start Date: 2020-05-15

Drug Details